{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:06:11Z","timestamp":1789668371600,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01653-w","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:30:48Z","timestamp":1789666248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Narrative and Tabular Synthesis: Introducing an Approach\u2013Rationale\u2013Note (ARN) Framework for Thematic Evidence Synthesis in Economic Evaluation Reviews"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4791-7866","authenticated-orcid":false,"given":"Mehdi","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-7274","authenticated-orcid":false,"given":"Amy","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-8492","authenticated-orcid":false,"given":"Jo","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-7381","authenticated-orcid":false,"given":"Somayeh","family":"Fazaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-3218","authenticated-orcid":false,"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"1653_CR1","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4th ed"},{"issue":"3","key":"1653_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40273-019-00878-2","volume":"38","author":"E Jacobsen","year":"2020","unstructured":"Jacobsen E, Boyers D, Avenell A. Challenges of systematic reviews of economic evaluations: a review of recent reviews and an obesity case study. Pharmacoeconomics. 2020;38(3):259\u201367.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1653_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","volume":"16","author":"B Wijnen","year":"2016","unstructured":"Wijnen B, Van Mastrigt G, Redekop WK, Majoie H, De Kinderen R, Evers S. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):723\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1653_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01536-x","volume":"9","author":"GE Shields","year":"2020","unstructured":"Shields GE, Elvidge J. Challenges in synthesising cost-effectiveness estimates. Syst Rev. 2020;9(1):289.","journal-title":"Syst Rev"},{"issue":"7302","key":"1653_CR5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/bmj.322.7302.1596","volume":"322","author":"J Nixon","year":"2001","unstructured":"Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ. 2001;322(7302):1596\u20138.","journal-title":"BMJ"},{"issue":"2","key":"1653_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/S0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240\u20135.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"1653_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"7","key":"1653_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1177\/0272989X14526470","volume":"34","author":"T Mathes","year":"2014","unstructured":"Mathes T, Walgenbach M, Antoine SL, Pieper D, Eikermann M. Methods for systematic reviews of health economic evaluations: a systematic review, comparison, and synthesis of method literature. Med Decis Making. 2014;34(7):826\u201340.","journal-title":"Med Decis Making"},{"issue":"3","key":"1653_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hec.1486","volume":"19","author":"R Anderson","year":"2010","unstructured":"Anderson R. Systematic reviews of economic evaluations: utility or futility. Health Econ. 2010;19(3):350\u201364.","journal-title":"Health Econ"},{"issue":"6996","key":"1653_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.311.6996.42","volume":"311","author":"C Pope","year":"1995","unstructured":"Pope C, Mays N. Reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research. BMJ. 1995;311(6996):42\u20135.","journal-title":"BMJ"},{"issue":"1","key":"1653_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/135581960501000110","volume":"10","author":"M Dixon-Woods","year":"2005","unstructured":"Dixon-Woods M, Agarwal S, Jones D, Young B, Sutton A. Synthesising qualitative and quantitative evidence: a review of possible methods. J Health Serv Res Policy. 2005;10(1):45\u201353.","journal-title":"J Health Serv Res Policy"},{"key":"1653_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-8-45","volume":"8","author":"J Thomas","year":"2008","unstructured":"Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8:45.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1653_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2288-9-59","volume":"9","author":"E Barnett-Page","year":"2009","unstructured":"Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9(1):59.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1653_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","volume":"62","author":"S Elo","year":"2008","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107\u201315.","journal-title":"J Adv Nurs"},{"issue":"1","key":"1653_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/nur.20176","volume":"30","author":"M Sandelowski","year":"2007","unstructured":"Sandelowski M, Barroso J, Voils CI. Using qualitative metasummary to synthesize qualitative and quantitative descriptive findings. Res Nurs Health. 2007;30(1):99\u2013111.","journal-title":"Res Nurs Health"},{"issue":"4","key":"1653_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1017\/S0266462311000389","volume":"27","author":"N Ring","year":"2011","unstructured":"Ring N, Jepson R, Ritchie K. Methods of synthesizing qualitative research studies for health technology assessment. Int J Technol Assess Health Care. 2011;27(4):384\u201390.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"1653_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04150-z","volume":"21","author":"M Yousefi","year":"2025","unstructured":"Yousefi M, Mehrabian A, Brown A, Butt F, Donoghue J, Parr J, et al. Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review. Orphanet J Rare Dis. 2025;21(1):10.","journal-title":"Orphanet J Rare Dis"},{"issue":"36","key":"1653_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta8360","volume":"8","author":"Z Philips","year":"2004","unstructured":"Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):1\u2013158.","journal-title":"Health Technol Assess"},{"key":"1653_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40258-024-00915-y","volume":"23","author":"S Khuntha","year":"2025","unstructured":"Khuntha S, Prawjaeng J, Ponragdee K, Sanmaneechai O, Srinonprasert V, Leelahavarong P. Onasemnogene abeparvovec gene therapy and risdiplam for the treatment of spinal muscular atrophy in Thailand: a cost-utility analysis. Appl Health Econ Health Policy. 2025;23:277\u201390.","journal-title":"Appl Health Econ Health Policy"},{"key":"1653_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:41.","journal-title":"Cost Eff Resour Alloc."},{"issue":"6","key":"1653_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2020.09.021","volume":"24","author":"TF Broekhoff","year":"2021","unstructured":"Broekhoff TF, Sweegers CCG, Krijkamp EM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG, et al. Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24(6):759\u201369.","journal-title":"Value Health"},{"key":"1653_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Onasemnogene abeparvovec for treating spinal muscular atrophy: highly specialised technologies guidance HST15. 2021. [2023 17 Feb 2025]. https:\/\/www.nice.org.uk\/guidance\/hst15."},{"issue":"12 Suppl","key":"1653_CR23","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jval.2023.09.360","volume":"26","author":"A Meijer","year":"2023","unstructured":"Meijer A, Omar AA. Cost-effectiveness analysis of onasemnogene abeparvovec-xioi (Zolgensma) and best supportive care treatment for spinal muscular atrophy I in the Netherlands with early-treatment scenario. Value Health. 2023;26(12 Suppl):S67.","journal-title":"Value Health."},{"key":"1653_CR24","unstructured":"Scottish Medicines Consortium (SMC). Onasemnogene abeparvovec 2 \u00d7 1013 vector genomes\/mL solution for infusion (Zolgensma\u00ae). SMC2311. 2021 [16 June 2025]. https:\/\/www.scottishmedicines.org.uk\/media\/5813\/onasemnogene-abeparvovec-zolgensma-final-feb-2021-amended-010321docx-for-website.pdf."},{"key":"1653_CR25","unstructured":"National Institute for Health and Care Excellence (NICE). Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy: highly specialised technologies guidance HST24. 2023 [17 Feb 2025]. https:\/\/www.nice.org.uk\/guidance\/hst24."},{"issue":"6","key":"1653_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","volume":"37","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019;37(6):845\u201365.","journal-title":"Pharmacoeconomics"},{"key":"1653_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). Nusinersen for treating spinal muscular atrophy: technology appraisal guidance TA588. 2019 [16 June 2025]. https:\/\/www.nice.org.uk\/guidance\/ta588."},{"key":"1653_CR28","unstructured":"Scottish Medicines Consortium (SMC). Nusinersen 12mg solution for injection (Spinraza\u00ae). SMC No 1318\/18. 2018 [16 June 2025]. https:\/\/www.scottishmedicines.org.uk\/media\/3415\/nusinersen-spinraza-final-april-2018-for-website.pdf."},{"key":"1653_CR29","unstructured":"National Centre for Pharmacoeconomics (Ireland). Cost-effectiveness of nusinersen (Spinraza) for the treatment of 5q spinal muscular atrophy (SMA). 2017 [16 June 2025]. https:\/\/ncpe.ie\/wp-content\/uploads\/2017\/08\/Summary-Nusinersen.pdf."},{"key":"1653_CR30","unstructured":"CADTH. Pharmacoeconomic review report (resubmission): nusinersen (Spinraza). CADTH Common Drug Review. 2019 [16 June 2025]. https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0576-spinraza-resubmission-pharmacoeconomic-report.pdf."},{"key":"1653_CR31","unstructured":"National Institute for Health and Care Excellence (NICE). Risdiplam for treating spinal muscular atrophy: technology appraisal guidance TA755. 2021 [15 December 2023, 17 Feb 2025]. https:\/\/www.nice.org.uk\/guidance\/ta755."},{"key":"1653_CR32","doi-asserted-by":"crossref","unstructured":"CADTH. CADTH reimbursement review: risdiplam (Evrysdi). Can J Health Technol. 2021 [16 June 2025]. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2021\/SR0661-combined-report-final.pdf.","DOI":"10.51731\/cjht.2021.136"},{"issue":"1","key":"1653_CR33","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841.","journal-title":"J Mark Access Health Policy."},{"key":"1653_CR34","unstructured":"CADTH. Pharmacoeconomic report: onasemnogene abeparvovec (Zolgensma). CADTH Common Drug Review. 2021 [16 June 2025]. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2021\/sg0649-zolgensma-pharmacoeconomic-review-report.pdf."},{"key":"1653_CR35","unstructured":"Ellis AG, Mickle K, Herron-Smith S, Kumar VM, Cianciolo L, Seidner M, et al. Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value: final evidence report. 2019. [16 June 2025]. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_110220.pdf."},{"issue":"7","key":"1653_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14712598.2020.1772747","volume":"20","author":"M Connock","year":"2020","unstructured":"Connock M, Andronis L, Auguste P, Dussart C, Armoiry X. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent \u201cvalue for money\u201d for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opin Biol Ther. 2020;20(7):823\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"1653_CR37","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1007\/s00415-022-11319-0","volume":"269","author":"T Wang","year":"2022","unstructured":"Wang T, Scuffham P, Byrnes J, Downes M. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia. J Neurol. 2022;269(12):6544\u201354.","journal-title":"J Neurol"},{"key":"1653_CR38","unstructured":"Scottish Medicines Consortium (SMC). Risdiplam 0.75mg\/mL powder for oral solution (Evrysdi\u00ae). 2022 [16 June 2025]. https:\/\/www.scottishmedicines.org.uk\/media\/6976\/risdiplam-evrysdi-final-jan-2022-amended-040722-for-website.pdf."},{"issue":"1","key":"1653_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484.","journal-title":"J Mark Access Health Policy"},{"issue":"5","key":"1653_CR40","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rav\u00e0 L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314.","journal-title":"Pediatrics"},{"issue":"1","key":"1653_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372.","journal-title":"J Neurol Sci"},{"issue":"6","key":"1653_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"issue":"9","key":"1653_CR43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"11","key":"1653_CR44","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","volume":"26","author":"R De Sanctis","year":"2016","unstructured":"De Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone ES, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26(11):754\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"1653_CR45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"9","key":"1653_CR46","doi-asserted-by":"publisher","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","volume":"20","author":"R Thompson","year":"2017","unstructured":"Thompson R, Vaidya S, Teynor M. The utility of different approachs to developing health utilities data in childhood rare diseases \u2013 a case study in spinal muscular atrophy (SMA). Value Health. 2017;20(9):A725\u20136.","journal-title":"Value Health"},{"issue":"9","key":"1653_CR47","doi-asserted-by":"publisher","first-page":"A559","DOI":"10.1016\/j.jval.2017.08.911","volume":"20","author":"A Lloyd","year":"2017","unstructured":"Lloyd A, Gallop K, Thompson R, Vaidya S, Teynor M. Estimation of the health-related quality of life benefits of treatment for spinal muscular atropy (SMA). Value Health. 2017;20(9):A559.","journal-title":"Value Health"},{"key":"1653_CR48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/CEOR.S214084","volume":"11","author":"AJ Lloyd","year":"2019","unstructured":"Lloyd AJ, Thompson R, Gallop K, Teynor M. Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy. Clinicoecon Outcomes Res. 2019;11:615\u201322.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"4","key":"1653_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539\u201345.","journal-title":"Value Health"},{"key":"1653_CR50","unstructured":"Nederland PnbSZ. Pakketadvies sluisgeneesmiddel nusinersen (Spinraza\u00ae) voor de behandeling van spinale musculaire atrofie (SMA). 2018."},{"key":"1653_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oup Oxford; 2006."},{"issue":"7","key":"1653_CR52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hec.1093","volume":"15","author":"MJ Sculpher","year":"2006","unstructured":"Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677\u201387.","journal-title":"Health Econ"},{"issue":"4","key":"1653_CR53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355\u201371.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01653-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01653-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01653-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:31:05Z","timestamp":1789666265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01653-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":53,"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01653-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in this study were derived from previously published sources.","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MY conceived the study and led the project. MY and PA developed the framework specification for the thematic synthesis of economic evaluations and conducted the thematic evidence synthesis. All authors contributed to the development of the methodological approach, participated in drafting the manuscript, and approved the final version.","order":4,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}